SCHEMBL4843210

SCHEMBL4843210

COc1ccccc1CNc1ccc(-c2nc3cc(Br)cnc3[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.50
ABL1 P00519 2/20 0.49
SRC P12931 2/20 0.49
EGFR P00533 2/20 0.45
AKT1 P31749 1/20 0.45
HPSE Q9Y251 2/20 0.44
GAA P10253 5/20 0.43
HSD17B10 Q99714 3/20 0.43
KDM1A O60341 1/20 0.43
RCOR1 Q9UKL0 1/20 0.43
ALDH1A1 P00352 6/20 0.43
MAPT P10636 5/20 0.43
KDM4E B2RXH2 4/20 0.43
HTT P42858 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 2/20 0.43
HPGD P15428 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4844143 0.91 ABL1 (0.49) ATMABL1SRCAKT1HPSE
SCHEMBL5258292 0.84 RAB9A (0.42) GAAALDH1A1MAPTNPC1RAB9A
SCHEMBL4844110 0.84 AKT1 (0.44) ATMAKT1
SCHEMBL4843616 0.82
SCHEMBL4834899 0.82 MMP2 (0.43) EGFRHPSEALDH1A1KDM4EHTT
SCHEMBL4843978 0.81 NPC1 (0.53) HPSEGAAHSD17B10ALDH1A1MAPT
SCHEMBL5258914 0.81 MAPT (0.48) EGFRHPSEGAAHSD17B10ALDH1A1
SCHEMBL27634140 0.80 HPSE (0.37) ABL1HPSEGAAMAPTNPC1
Trifluoroacetic Acid SCHEMBL4840500 0.77 BRD4 (0.42) ABL1SRCAKT1HPSEALDH1A1
SCHEMBL5258759 0.77 NPC1 (0.38) ABL1EGFRHPSEALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100358893-C Certain novel imidazopyridines and uses thereof ASTRAZENECA AB (SE) 2008-01-02 CN claimed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP claimed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US claimed
CN-1684964-A Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2005-10-19 CN claimed
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
CN-100358893-C Certain novel imidazopyridines and uses thereof ASTRAZENECA AB (SE) 2008-01-02 CN disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed
CN-1684964-A Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2005-10-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 ATM 620/4885ABL1 272/4885SRC 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.